ARCH Venture Partners XII, L.P.'s Net Worth
$478 Million
Who is ARCH Venture Partners XII, L.P.?
ARCH Venture Partners XII, L.P. has an estimated net worth of $478 Million. This is based on reported shares in Neumora Therapeutics, Inc..
SEC CIK
ARCH Venture Partners XII, L.P.'s CIK is 0001979765
Past Insider Trading and Trends
2023 was ARCH Venture Partners XII, L.P.'s most active year for acquiring shares with 24 total transactions. ARCH Venture Partners XII, L.P.'s most active month to acquire stocks was the month of August. 2023 was ARCH Venture Partners XII, L.P.'s most active year for disposing of shares, totalling 5 transactions. ARCH Venture Partners XII, L.P.'s most active month to dispose stocks was the month of August. 2023 saw ARCH Venture Partners XII, L.P. paying a total of $31,430,024.08 for 19,431,768 shares, this is the most they've acquired in one year. In 2023 ARCH Venture Partners XII, L.P. cashed out on 17,424,704 shares for a total of $0.00, their largest year based on trade value.
Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!
Neumora Therapeutics, Inc. (NMRA) Snapshot price: $16.96
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
| +102.76% | 1.88M |
—
|
—
| 3.71M |
Dec 8
| |||
Form 4
| +0.85% | 35.01K |
$11.77 | $412,139.61 | 4.13M |
Nov 13 - Nov 14
| |||
Form 4
| +3.55% | 140.6K |
$10.98 | $1,543,563.42 | 4.1M |
Nov 8 - Nov 10
| |||
Form 4
| +2.48% | 95.69K |
$11.49 | $1,099,944.70 | 3.96M |
Nov 3 - Nov 7
| |||
Form 4
| +2.02% | 76.51K |
$13.68 | $1,046,848.16 | 3.86M |
Sep 28 - Sep 29
| |||
Form 4
| +1.57% | 58.5K |
$11.97 | $700,464.24 | 3.78M |
Sep 26 - Sep 27
| |||
Form 4
| +2.78% | 100.74K |
$11.19 | $1,127,063.95 | 3.72M |
Sep 22 - Sep 25
| |||
Form 4
| +178.19% | 18.92M |
$17.00 |
—
| 29.55M |
Sep 19
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Rapport Therapeutics, Inc. No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.73M |
—
|
—
| 3.73M |
Jun 10
| |||
Form 3
|
—
|
0
|
—
|
—
|
0
| ||||
| No matching records found | |||||||||
Prime Medicine, Inc. (PRME) No price found
Investor
Form Type
|
Δ Own
|
Qty.
|
Price
|
Size ($)
|
Own
|
Filing Date
|
Type
|
Is Scheduled
|
Trade Dates
|
|---|---|---|---|---|---|---|---|---|---|
Form 4
|
∞
| 3.2M |
$6.25 | $20,000,000.00 | 3.2M |
Feb 15
| |||
| No matching records found | |||||||||